Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPC5 | Q9UL62 | 14/20 | 0.78 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17508800 | 0.90 | TRPC5 (0.76) | TRPC5CYP1A2HSD17B10ALDH1A1CYP3A4 | |
| SCHEMBL17508411 | 0.88 | TRPC5 (1.00) | TRPC5 | |
| SCHEMBL17508805 | 0.82 | TRPC5 (0.77) | TRPC5 | |
| SCHEMBL17508801 | 0.77 | TRPC5 (0.76) | TRPC5KMT2AMEN1TSHR | |
| SCHEMBL17508807 | 0.77 | TRPC5 (1.00) | TRPC5 | |
| SCHEMBL17508803 | 0.74 | TRPC5 (0.79) | TRPC5KMT2AMEN1TSHR | |
| SCHEMBL17508799 | 0.73 | TRPC5 (0.80) | TRPC5GRIN1GRIN2B | |
| SCHEMBL17546479 | 0.73 | TRPC5 (0.44) | TRPC5 | |
| SCHEMBL17508802 | 0.73 | TRPC5 (0.78) | TRPC5KMT2AMEN1TSHR | |
| SCHEMBL17508393 | 0.73 | TRPC5 (0.43) | TRPC5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3180337-B1 | PYRIDO[3,4-D]PYRIMIDINE-2,4(1H,3H)-DIONE DERIVATIVES | HYDRA BIOSCIENCES INC (US) | 2018-10-10 | — | — | EP | disclosed |
| EP-3180337-A1 | PYRIDO[3,4-D]PYRIMIDINE-2,4(1H,3H)-DIONE DERIVATIVES | Hydra Biosciences, Inc. (US) | 2017-06-21 | — | — | EP | disclosed |
| US-9440973-B2 | Pyrido[3,4-d]pyrimidine-2,4(1H,3H)-dione derivatives | HYDRA BIOSCIENCES, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9440973-B2 | Pyrido[3,4-d]pyrimidine-2,4(1H,3H)-dione derivatives | HYDRA BIOSCIENCES, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9440973-B2 | Pyrido[3,4-d]pyrimidine-2,4(1H,3H)-dione derivatives | HYDRA BIOSCIENCES, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| WO-2016023825-A1 | PYRIDO[3,4-D]PYRIMIDINE-2,4(1H,3H)-DIONE DERIVATIVES | HYDRA BIOSCIENCES, INC. (US) | 2016-02-18 | — | — | WO | disclosed |
| WO-2016023825-A1 | PYRIDO[3,4-D]PYRIMIDINE-2,4(1H,3H)-DIONE DERIVATIVES | HYDRA BIOSCIENCES, INC. (US) | 2016-02-18 | — | — | WO | disclosed |
| US-20160039815-A1 | PYRIDO[3,4-d]PYRIMIDINE-2,4(1H,3H)-DIONE DERIVATIVES | HYDRA BIOSCIENCES, INC. | 2016-02-11 | — | — | US | disclosed |
| US-20160039815-A1 | PYRIDO[3,4-d]PYRIMIDINE-2,4(1H,3H)-DIONE DERIVATIVES | HYDRA BIOSCIENCES, INC. | 2016-02-11 | — | — | US | disclosed |
| US-20160039815-A1 | PYRIDO[3,4-d]PYRIMIDINE-2,4(1H,3H)-DIONE DERIVATIVES | HYDRA BIOSCIENCES, INC. | 2016-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039815-A1 | PYRIDO[3,4-d]PYRIMIDINE-2,4(1H,3H)-DIONE DERIVATIVES | TRPC5, P2RX5, HTR5A | TRPC5 1/4885CYP1A2 1054/4885HSD17B10 3528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.